SEMA3E and systemic sclerosis: Thus, we believe that further insights into the potential diagnostic value of these markers could arise from future longitudinal studies monitoring changes in circulating levels of sNRP1 and Sema3E in VEDOSS patients who progress into an established SSc disease.